Key result
Measurement of serum ivabradine levels confirmed toxicity in a 43-year-old female presenting with symptomatic bradycardia, with levels twice the expected maximum concentration.
Why the study?
There are limited reports in the literature describing symptomatic bradycardia resulting from ivabradine toxicity confirmed by measurement of ivabradine levels.
Case Report (n=1)
No
Measurement of serum ivabradine levels can confirm the diagnosis of ivabradine toxicity in patients presenting with unexplained symptomatic bradycardia.
May warrant considering ivabradine toxicity in unexplained bradycardia; case reports leave open need for validated diagnostic testing.
BACKGROUND: We describe a case of symptomatic bradycardia resulting from ivabradine toxicity by measurement of ivabradine levels, of which there are limited reports in the literature. CASE PRESENTATION: A 43-year-old White female presented with several days of near syncope and dizziness accompanied by a drop in her heart rate to 50 beats per minute. She was taking ivabradine for inappropriate sinus tachycardia. After excluding several other causes of bradycardia, we made the diagnosis of ivabradine toxicity by measurement of serum ivabradine levels, an approach that is currently not clinically available. CONCLUSIONS: Measurement of serum ivabradine levels and knowledge of the pharmacokinetic properties of the drug can be utilized to confirm the diagnosis of ivabradine toxicity.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2022) conducted a case report in Ivabradine toxicity (n=1). Ivabradine was evaluated on Diagnosis of ivabradine toxicity via serum levels. Measurement of serum ivabradine levels confirmed toxicity in a 43-year-old female presenting with symptomatic bradycardia, with levels twice the expected maximum concentration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: